Bausch Health Cos Inc. (BHC) – What Are Brokerages Thinking About This Stock?

Shares of Bausch Health Cos Inc. (NYSE:BHC) have received an average recommendation of “Hold” from the seven ratings firms that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and one has issued a strong buy rating on the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $8.00.

Several research firms recently issued reports on BHC. Zacks Research raised shares of Bausch Health Cos from a “hold” rating to a “strong-buy” rating in a research note on Monday, September 21st. Weiss Ratings raised shares of Bausch Health Cos from a “sell (d-)” rating to a “sell (d)” rating in a research report on Friday, July 31st. Jefferies Financial Group upgraded Bausch Health Cos to a “hold” rating in a research note on Wednesday, July 22nd. Royal Bank Of Canada restated a “sector perform” rating and set a $9.00 target price on shares of Bausch Health Cos in a research note on Thursday. Finally, Wall Street Zen raised Bausch Health Cos from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 1st.

Bausch Health Cos Stock Down 1.9%

NYSE BHC opened at $5.92 on Tuesday. The stock has a market cap of $2.22 billion, a PE ratio of -2.00 and a beta of 0.37. Bausch Health Cos has a fifty-two week low of $4.33 and a fifty-two week high of $8.00. The business has a 50 day moving average price of $6.18 and a two-hundred day moving average price of $5.57.

Bausch Health Cos (NYSE:BHC) last issued its quarterly earnings data on Wednesday, July 29th. The company reported $1.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.96 by $0.30. The company had revenue of $2.83 billion during the quarter, compared to the consensus estimate of $2.59 billion. Bausch Health Cos had a negative net margin of 10.12% and a negative return on equity of 561.95%. Sell-side analysts anticipate that Bausch Health Cos will post 4.35 EPS for the current fiscal year.

Insider Buying and Selling

In other Bausch Health Cos news, insider Aimee Lenar sold 36,827 shares of the firm’s stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $7.03, for a total transaction of $258,893.81. Following the completion of the sale, the insider owned 334,853 shares in the company, valued at $2,354,016.59. This trade represents a 9.91% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 20.67% of the company’s stock.

Hedge Funds Weigh In On Bausch Health Cos

Institutional investors have recently made changes to their positions in the business. Paulson & CO. Inc. purchased a new position in shares of Bausch Health Cos during the 2nd quarter valued at approximately $361,151,000. MFN Partners Management LP bought a new stake in shares of Bausch Health Cos in the second quarter worth $29,580,000. Royal Bank of Canada increased its stake in shares of Bausch Health Cos by 24.9% in the first quarter. Royal Bank of Canada now owns 11,363,498 shares of the company’s stock worth $61,362,000 after buying an additional 2,262,894 shares during the last quarter. Man Group plc bought a new stake in shares of Bausch Health Cos in the second quarter worth $7,157,000. Finally, Bank of America Corp DE acquired a new stake in shares of Bausch Health Cos in the 2nd quarter valued at about $2,816,000. 78.65% of the stock is owned by institutional investors and hedge funds.

About Bausch Health Cos

Bausch Health Companies Inc is a multinational specialty pharmaceutical company headquartered in Laval, Quebec. The company develops, manufactures and markets prescription medicines, branded and generic pharmaceuticals, over-the-counter products and medical devices across a range of therapeutic areas.

Its business includes Salix Pharmaceuticals, which focuses on gastrointestinal treatments; Ortho Dermatologics, which develops prescription therapies for dermatological conditions; and Solta Medical, which provides energy-based medical and aesthetic devices.